Association of Homocysteine with Cardiac Markers and Inflammatory Indicators in Cardiovascular Diseases: A Comparative Study

<i>Background</i>: Hyperhomocysteinemia is an emerging risk factor for cardiovascular diseases (CVDs) and diabetes-related complications. <i>Objective</i>: This study aimed to evaluate the correlation between homocysteine and various biochemical markers to better understand their role in cardiovascular and metabolic risk. <i>Methods</i>: This observational cross-sectional study consisted of a total of 234 participants divided into three predefined groups: Group A (healthy individuals), Group B (nondiabetic cardiac patients), and Group C (diabetic cardiac patients). The biochemical markers, including homocysteine, total leukocyte count (TLC), erythrocyte sedimentation rate (ESR), cholesterol, triglycerides (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL), were measured. The correlation analysis and one-way analysis of variance (ANOVA) were used for statistical evaluation. <i>Results</i>: The homocysteine levels were significantly elevated in Groups B and C compared to Group A (<i>p</i> < 0.05). A weak positive correlation was observed between homocysteine and erythrocyte sedimentation rate in Groups B and C, with statistical significance (<i>r</i> = 0.36, <i>p</i> = 0.049; <i>r</i> = 0.37, <i>p</i> = 0.044, respectively). The lipid profile parameters differed significantly among groups, but the correlations between homocysteine and lipid markers were weak and nonsignificant. A significant difference (<i>p</i> < 0.05) was observed among the groups for all measured biochemical parameters. <i>Conclusions</i>: Elevated homocysteine levels, particularly in cardiac and diabetic patients, are associated with inflammation (as indicated by the erythrocyte sedimentation rate). The findings highlight the potential of homocysteine as a biomarker for cardiovascular and metabolic risk. Further studies are warranted to evaluate its therapeutic implications.